Eloxx Pharmaceuticals, Inc. (ELOX)
OTCMKTS · Delayed Price · Currency is USD
0.0875
-0.0725 (-45.31%)
Mar 26, 2026, 3:56 PM EST
Eloxx Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
811.51K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 6.36M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SQZ Biotechnologies Company | 12.12M |
| Emmaus Life Sciences | 11.89M |
| EV Biologics | 9.47M |
| Scorpius Holdings | 1.72M |
| Lyra Therapeutics | 600.00K |
| Lipella Pharmaceuticals | 389.78K |
| THC Farmaceuticals | 18.52K |
Eloxx Pharmaceuticals News
- 1 year ago - Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases - Business Wire
- 2 years ago - Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome - GlobeNewsWire